Cargando…

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?

Detalles Bibliográficos
Autores principales:	Mihály, Zsuzsanna, Panajotu, Alexisz, Győrffy, Balázs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708253/ https://www.ncbi.nlm.nih.gov/pubmed/26816708 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.06.07

Ejemplares similares

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis
por: Mihály, Zsuzsanna, et al.
Publicado: (2013)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

The fungal mycobiome: a new hallmark of cancer revealed by pan-cancer analyses
por: Zong, Zhi, et al.
Publicado: (2023)

Compartmentalized multicellular crosstalk in lymph nodes coordinates the generation of potent cellular and humoral immune responses
por: Poirot, Justine, et al.
Publicado: (2021)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

The effect of four-phasic versus three-phasic contrast media injection protocols on extravasation rate in coronary CT angiography: a randomized controlled trial
por: Karády, Júlia, et al.
Publicado: (2017)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Engrafted newborn neurons could functionally integrate into the host neuronal network
por: Wang, Zheng-Bo, et al.
Publicado: (2017)

A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment
por: Ng, Susanna S., et al.
Publicado: (2021)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

On the road to epigenetic therapy
por: Walton, Emma L.
Publicado: (2016)

“Armed for the future Coronavirus pandemic”: a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine
por: Kumar, Manoj, et al.
Publicado: (2021)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Towards gene therapy for IPEX syndrome
por: Borna, Simon, et al.
Publicado: (2022)

Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study
por: Zhong, Lei, et al.
Publicado: (2023)

New waves underneath the purple strain
por: Tortajada, Marta
Publicado: (2016)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

Metabolic engineering, new antibiotics and biofilm viscoelasticity
por: Daniels, Craig, et al.
Publicado: (2010)

Microbiomes as the new keystone for life sciences development
por: Udaondo, Zulema, et al.
Publicado: (2019)

Modulating serine palmitoyltransferase‐deoxysphingolipid axis in cancer therapy
por: Xiang, Yuancai, et al.
Publicado: (2020)

Bioinformatics Analysis of Prognostic Value of SPC24 in ccRCC and Pan-Cancer
por: Zhang, Jipeng, et al.
Publicado: (2022)

Sex First—A New View of the Origins of Eukaryotes
por: Venton, Danielle
Publicado: (2017)

Highlight: Shining New Light on Coral Fluorescent Proteins
por: Venton, Danielle
Publicado: (2017)

Highlight: A Search for New Species on the High Seas
por: McGrath, Casey
Publicado: (2020)

Highlight: Yellow is the New Black for Gobi Desert Lizards
por: McGrath, Casey
Publicado: (2022)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_61pjq38s032d1mfdrjthml0kad